Novo Nordisk (NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N.

Novo Nordisk (NYSE:NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and ...

The main brands distributed by Novo Nordisk in this market include Tresiba, Xultophy, Levemir, NovoMix, Fiasp and NovoRapid; on the other hand, Eli Lilly distributes the Basaglar, Humalog ...

Novo Nordisk (NYSE:NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N. Overall, NVO ranks 6th on our list of firms that took a hit on ...

Novo and competitors such as Sanofi and Eli ... and which now outsells its biggest insulin product, Levemir, which saw its revenues decline in 2016. FDA insistence that companies must undertake ...

Meanwhile Novo Nordisk has also seen its ranking surge ... strong performances from GLP-1 analogue Victoza, insulin analogue Levemir and the 2015 launch of longer-acting insulin analogue Tresiba.

Jan 28 (Reuters) - The U.S. FDA has approved Novo Nordisk's (NOVOb.CO), opens new tab Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with ...